SEARCH

SEARCH BY CITATION

REFERENCES

  • 1
    Maini RN, Taylor PC, Szechinski J, Pavelka K, Broll J, Balint G, et al, for the CHARISMA Study Group.Double-blind randomized controlled clinical trial of the interleukin-6 receptor antagonist, tocilizumab, in European patients with rheumatoid arthritis who had an incomplete response to methotrexate.Arthritis Rheum2006;54:281729.
  • 2
    Smolen JS, Beaulieu A, Rubbert-Roth A, Ramos-Remus C, Rovensky J, Alecock E, et al.Effect of interleukin-6 receptor inhibition with tocilizumab in patients with rheumatoid arthritis (OPTION study): a double-blind, placebo-controlled, randomised trial.Lancet2008;371:98797.
  • 3
    Genovese MC, McKay JD, Nasonov EL, Mysler EF, da Silva NA, Alecock E, et al.Interleukin-6 receptor inhibition with tocilizumab reduces disease activity in rheumatoid arthritis with inadequate response to disease-modifying antirheumatic drugs: the Tocilizumab in Combination With Traditional Disease-Modifying Antirheumatic Drug Therapy study.Arthritis Rheum2008;58:296880.
  • 4
    Badot V, Galant C, Nzeusseu Toukap A, Theate I, Maudoux AL, Van den Eynde BJ, et al.Gene expression profiling in the synovium identifies a predictive signature of absence of response to adalimumab therapy in rheumatoid arthritis.Arthritis Res Ther2009;11:R57.
  • 5
    Gutierrez-Roelens I, Galant C, Theate I, Lories RJ, Durez P, Nzeusseu-Toukap A, et al.Rituximab treatment induces the expression of genes involved in healing processes in the rheumatoid arthritis synovium.Arthritis Rheum2011;63:124654.
  • 6
    Arnett FC, Edworthy SM, Bloch DA, McShane DJ, Fries JF, Cooper NS, et al.The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis.Arthritis Rheum1988;31:31524.
  • 7
    Prevoo ML, van 't Hof MA, Kuper HH, van Leeuwen MA, van de Putte LB, van Riel PL.Modified disease activity scores that include twenty-eight–joint counts: development and validation in a prospective longitudinal study of patients with rheumatoid arthritis.Arthritis Rheum1995;38:448.
  • 8
    Smolen JS, Breedveld FC, Schiff MH, Kalden JR, Emery P, Eberl G, et al.A Simplified Disease Activity Index for rheumatoid arthritis for use in clinical practice.Rheumatology (Oxford)2003;42:24457.
  • 9
    Van Gestel AM, Prevoo ML, van 't Hof MA, van Rijswijk MH, van de Putte LB, van Riel PL.Development and validation of the European League Against Rheumatism response criteria for rheumatoid arthritis: comparison with the preliminary American College of Rheumatology and the World Health Organization/International League Against Rheumatism criteria.Arthritis Rheum1996;39:3440.
  • 10
    Boyle DL, Rosengren S, Bugbee W, Kavanaugh A, Firestein GS.Quantitative biomarker analysis of synovial gene expression by real-time PCR.Arthritis Res Ther2003;5:R35260.
  • 11
    Gerlag DM, Tak PP.How to perform and analyse synovial biopsies.Best Pract Res Clin Rheumatol2009;23:22132.
  • 12
    Nzeusseu Toukap A, Galant C, Theate I, Maudoux AL, Lories RJ, Houssiau FA, et al.Identification of distinct gene expression profiles in the synovium of patients with systemic lupus erythematosus.Arthritis Rheum2007;56:157988.
  • 13
    Irizarry RA, Hobbs B, Collin F, Beazer-Barclay YD, Antonellis KJ, Scherf U, et al.Exploration, normalization, and summaries of high density oligonucleotide array probe level data.Biostatistics2003;4:24964.
  • 14
    Huang DW, Sherman BT, Lempicki RA.Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources.Nat Protoc2009;4:4457.
  • 15
    Aletaha D, Smolen J.The Simplified Disease Activity Index (SDAI) and the Clinical Disease Activity Index (CDAI): a review of their usefulness and validity in rheumatoid arthritis.Clin Exp Rheumatol2005;23:S1008.
  • 16
    Lipsky PE.Interleukin-6 and rheumatic diseases.Arthritis Res Ther2006;8 Suppl 2:S4.
  • 17
    Houssiau FA, Devogelaer JP, Van Damme J, de Deuxchaisnes CN, Van Snick J.Interleukin-6 in synovial fluid and serum of patients with rheumatoid arthritis and other inflammatory arthritides.Arthritis Rheum1988;31:7848.
  • 18
    Houssiau FA, Coulie PG, Olive D, Van Snick J.Synergistic activation of human T cells by interleukin 1 and interleukin 6.Eur J Immunol1988;18:6536.
  • 19
    Houssiau FA, Coulie PG, Van Snick J.Distinct roles of IL-1 and IL-6 in human T cell activation.J Immunol1989;143:25204.
  • 20
    Bettelli E, Carrier Y, Gao W, Korn T, Strom TB, Oukka M, et al.Reciprocal developmental pathways for the generation of pathogenic effector TH17 and regulatory T cells.Nature2006;441:2358.
  • 21
    Field M, Chu C, Feldmann M, Maini RN.Interleukin-6 localisation in the synovial membrane in rheumatoid arthritis.Rheumatol Int1991;11:4550.
  • 22
    Van de Veerdonk FL, Lauwerys B, Marijnissen RJ, Timmermans K, Di Padova F, Koenders MI, et al.The anti-CD20 antibody rituximab reduces the Th17 cell response.Arthritis Rheum2011;63:150716.
  • 23
    You S, Cho CS, Lee I, Hood L, Hwang D, Kim WU.A systems approach to rheumatoid arthritis.PloS One2012;7:e51508.
  • 24
    Isaacs JD, Cohen SB, Emery P, Tak PP, Wang J, Lei G, et al.Effect of baseline rheumatoid factor and anticitrullinated peptide antibody serotype on rituximab clinical response: a meta-analysis.Ann Rheum Dis2013;72:32936.
  • 25
    Dougados M, Kissel K, Sheeran T, Tak PP, Conaghan PG, Mola EM, et al.Adding tocilizumab or switching to tocilizumab monotherapy in methotrexate inadequate responders: 24-week symptomatic and structural results of a 2-year randomised controlled strategy trial in rheumatoid arthritis (ACT-RAY).Ann Rheum Dis2013;72:4350.
  • 26
    Klareskog L, van der Heijde D, de Jager JP, Gough A, Kalden J, Malaise M, et al, for the TEMPO (Trial of Etanercept and Methotrexate with Radiographic Patient Outcomes) study investigators.Therapeutic effect of the combination of etanercept and methotrexate compared with each treatment alone in patients with rheumatoid arthritis: double-blind randomised controlled trial.Lancet2004;363:67581.